The Institute for Neurodegenerative Disorders

What The Institute for Neurodegenerative Disorders does

The Institute for Neurodegenerative Disorders (IND) is an independent 501(c)(3) nonprofit research institute headquartered in New Haven, Connecticut, founded in 2000 by neurologists Kenneth Marek, MD and John Seibyl, MD. The institute specializes in clinical research and functional brain imaging for Parkinson's disease, Alzheimer's disease, and Huntington's disease, using Positron Emission Tomography (PET) and Single Photon Emission Computerized Tomography (SPECT) to detect neurochemical changes, support early diagnosis, and monitor disease progression. IND's proprietary dopamine transporter SPECT imaging has demonstrated approximately 98% sensitivity in discriminating Parkinson's disease from healthy subjects, and its amyloid imaging capabilities support early Alzheimer's detection and differentiation from other dementias.

IND operates a single clinical research site in New Haven but functions as the coordinating principal investigator for the Michael J. Fox Foundation's Parkinson's Progression Markers Initiative (PPMI), spanning 33 clinical sites across 11 countries. The institute conducts Phase II through Phase IV clinical trials in partnership with pharmaceutical and biotechnology companies — including Roche/Genentech (Prasinezumab), Eli Lilly (Donanemab), Biogen/Eisai (Lecanemab), and Biohaven (BHV-8000) — and engages more than 1,000 research participants annually drawn primarily from New England, the broader US, and Canada.

IND is funded through a mix of foundation grants, federal and state grants, corporate and individual donations, and clinical trial service revenue; the institute does not charge patients for any services. Its leadership team combines the co-founder scientists with a pharma-experienced COO (joined April 2021, with prior NDA/sNDA leadership), a movement-disorders neurologist CMO, a CFO with prior neuroimaging CRO experience, and VPs overseeing data strategy, research operations, and new strategic initiatives. The institute's strategic positioning is anchored in neuroimaging protocol expertise, longitudinal biomarker data assets (notably via PPMI), and embedded relationships across major neurodegenerative disease research funders and pharma sponsors.

Name

The Institute for Neurodegenerative Disorders

Legal name

The Institute for Neurodegenerative Disorders

Website

https://indd.org

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

101–250 employees

Short description

The Institute for Neurodegenerative Disorders is a New Haven-based nonprofit research institute conducting clinical trials and PET/SPECT brain imaging research for Parkinson's, Alzheimer's, and Huntington's diseases, partnering with pharmaceutical companies and foundations including the Michael J. Fox Foundation.

Ownership category

akta.pro rank

Headquarters

HQ city

New Haven

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. Foundation and Grant Funding: IND is a 501(c)(3) nonprofit that depends on support from foundations and federal/state grants to fund its research mission.
2. Corporate and Individual Contributions: Support from corporations and individual donors who contribute to advance the institute's mission of developing diagnostic tools and treatments for neurodegenerative conditions.
3. Clinical Trial Partnerships: Partnerships with pharmaceutical companies for clinical trial execution, evaluating new symptomatic treatments and disease-modifying medications.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

The Institute for Neurodegenerative Disorders (IND) is a 501(c)(3) nonprofit clinical research institute that conducts clinical trials and brain imaging research for neurodegenerative disorders including Parkinson's disease, Alzheimer's disease, and Huntington's disease. IND recruits research participants and serves as a clinical trial site for pharmaceutical and biotech sponsors, leveraging PET and SPECT imaging to develop biomarkers for early diagnosis, disease progression monitoring, and therapy evaluation.

Product overview

IND is a clinical research institute, not a technology product company. Its offerings consist of clinical research services focused on neurodegenerative disorders (Parkinson's, Alzheimer's, and Huntington's diseases), brain imaging research using PET and SPECT modalities, biomarker development for early detection and disease monitoring, and participation in the PPMI study. The institute operates as a unified research program rather than a platform with discrete commercial products. Services are provided free of charge to research participants as a nonprofit scientific research institute.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Research Services End-to-end clinical trial execution for pharmaceutical and biotech sponsors, including participant recruitment, clinical assessment, imaging protocols, and data delivery for studies of investigational therapies targeting Parkinson's, Alzheimer's, and Huntington's disease.
• Brain Imaging Research (PET and SPECT) Specialized PET and SPECT brain imaging studies for clinical research protocols, including dopamine transporter imaging (DAT-SPECT), amyloid PET, and tau PET imaging to support diagnostic, progression, and therapeutic monitoring research in neurodegenerative disorders.
• Biomarker Development Research service focused on discovery, validation, and qualification of imaging and molecular biomarkers for early diagnosis and disease progression monitoring in Parkinson's, Alzheimer's, and Huntington's disease, including novel PET ligands and quantitative imaging endpoints.

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core.

• The Michael J. Fox FoundationcoreStrategic or Co-development PartnerIND has an ongoing research partnership with The Michael J. Fox Foundation. Dr. Kenneth Marek serves on the foundation's scientific advisory board and is coordinating principal investigator for the PPMI (Parkinson's Progression Markers Initiative) study sponsored by the foundation. This partnership enables IND to participate in major international research initiatives for Parkinson's disease.
• Roche/GenentechcoreStrategic or Co-development PartnerIND is conducting Phase II and Phase III clinical trials evaluating Prasinezumab (RO7046015/PRX002), an investigational antibody therapy for Parkinson's disease developed by Roche/Genentech.
• Biohaven Pharmaceuticals (BHV-8000)coreStrategic or Co-development PartnerIND is conducting a Phase 2/3 clinical trial evaluating BHV-8000, an investigational drug targeting brain inflammation in early Parkinson's disease patients.
• Eli Lilly (Donanemab)coreStrategic or Co-development PartnerIND is conducting the TRAILBLAZER-ALZ 2 trial evaluating Donanemab, an amyloid-targeting antibody therapy for early Alzheimer's disease developed by Eli Lilly.
• Biogen/Eisai (Lecanemab)coreStrategic or Co-development PartnerIND is conducting clinical trials for Lecanemab, an anti-amyloid antibody therapy for early Alzheimer's disease developed by Biogen and Eisai.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Banner Alzheimer's Institute: Banner Alzheimer's Institute is a nonprofit dedicated to Alzheimer's disease research, conducting clinical trials and amyloid/tau imaging studies. It is a direct peer in neurodegenerative disease research site operations and biomarker development.
• Barrow Neurological Institute: Barrow Neurological Institute is a major specialty center for neurology and neurosurgery with active neurodegenerative disease clinical trials and neuroimaging research. It is a direct peer in CNS clinical research site operations.
• Molecular NeuroImaging: Molecular NeuroImaging is a specialized PET/SPECT imaging research organization with deep roots in the same Yale-affiliated neuroimaging community that spawned IND. It is the closest direct peer in terms of molecular imaging for CNS research and shares prior executive lineage with IND.
• Invicro: Invicro is a molecular imaging CRO offering PET/SPECT imaging services to pharma sponsors, with overlap in CNS and neurodegenerative trial imaging. IND's COO and CFO both previously held executive roles at Invicro/Molecular NeuroImaging, indicating direct functional comparability.
• Cleveland Clinic Lou Ruvo Center for Brain Health: The Lou Ruvo Center for Brain Health runs clinical trials and neuroimaging research for Alzheimer's, Parkinson's, and Huntington's diseases. It is a direct peer as a specialized neurodegenerative clinical research site with pharma-sponsored trial activity.

Broad incumbents

• IXICO: IXICO is a neuroimaging CRO specializing in CNS clinical trials, providing image analysis and biomarker services to pharma sponsors. It is a broad incumbent with overlapping neurodegenerative trial imaging services, though it is software/services focused rather than a clinical site.
• Clario (formerly Bioclinica): Clario is a large clinical research organization with extensive imaging services including PET/SPECT for CNS trials. It serves as a broad incumbent with overlapping neuroimaging trial services but operates across many therapeutic areas beyond neurodegeneration.
• Cogstate: Cogstate is a cognitive assessment and clinical trial technology company serving CNS drug development, including neurodegenerative indications. IND's CFO previously worked at Cogstate, indicating direct functional overlap in CNS clinical trial operations.
• Yale University School of Medicine (Movement Disorders Center): Yale's Movement Disorders Center is where IND's co-founders previously led Parkinson's research and imaging. It remains a broad academic incumbent with comparable neurodegenerative clinical trial and imaging research capabilities.
• Massachusetts General Hospital (Neurology): Massachusetts General Hospital runs major neurodegenerative clinical trials and PET/SPECT imaging research, with broader scope and resources than IND. It is a broad incumbent in the academic CNS research site space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about The Institute for Neurodegenerative Disorders